Discussing in "Multiple Myeloma"

The changing landscape of induction therapy for newly diagnosed multiple myeloma Elias Mai, MD, University Hospital Heidelberg, Heidelberg, Germany, outlines new agents added to induction strategies in patients with newly diagnosed transplant-eligible multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Approved and emerging CAR-Ts in multiple myeloma Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, comments on the efficacy and safety of idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), two chimeric antigen receptor T-cell (CAR-T) therapies for multiple myeloma. Ide-cel has been approved by the FDA and EMA for patients with multiple myeloma who […]

Improving the management of multiple myeloma Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, briefly explains the importance of accurate evaluation of patients with multiple myeloma. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.

Benefits of CELMoDs over IMiDs in multiple myeloma Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, comments on the differences between cereblon E3 ligase modulators (CELMoDs) including iberdomide and CC-92480 and immunomodulatory imide drugs (IMiDs) in the treatment of multiple myeloma. Whilst these compounds appear structurally similar to IMiDs, they are significantly […]

About MGUS and Smouldering Multiple Myeloma Presented by: Dr Omar Nadeem Jerome Lipper Multiple Myeloma Center Clinical Director, Myeloma Cellular Therapies Program Dana-Farber Cancer Institute Instructor in Medicine, Harvard Medical School Boston, MA

plasma cell dyscrasia || Hematology

COMy 2016: new developments in multiple myeloma Thierry Facon, MD, PhD, from Hospital Claude Huriez, Lille, France provides an overview of the topics and sessions covered at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) held in Paris, France. Some of the areas covered at the meetings were the biology and genetics of […]

Why more people are surviving blood cancer | Dr. Aaron Schimmer on CBC's Metro morning Precision medicine is helping more people survive blood cancer, and the future looks even brighter. Find out why from Dr. Aaron Schimmer, acute leukaemia physician and director of research at Princess Margaret Cancer Centre, in conversation with Matt Galloway of […]

Caring for older adults with blood cancers | Dana-Farber Cancer Institute In this video, Dr. Tammy Hsieh describes the role she plays as a geriatrician in the Older Adult Hematologic Malignancy Program at Dana-Farber. Through this program, Dr. Hshieh co-manages a patient’s care with Dana-Farber’s oncologists, and helps identify and manage an older patient’s medical, […]